A scalable manufacturing platform for externally controllable universal CAR T-cell products

Basic Information

Funding Cycle : 2023-2024
Name : Kiyosumi Ochi
Type of Award : Career Development Award
Home Institution : The Institute of Medical Science, The University of Tokyo, Japan
Host Institution : Massachusetts General Hospital


Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in cancer treatment and has achieved unprecedented success in hematologic malignancies. Recent advances in autologous CAR T-cell therapies utilize a patient’s own immune T cells, but “”off-the-shelf”” allogeneic CAR T cells have many potential advantages over autologous approaches, including immediate availability of cryopreserved batches, potential standardization of the cell product, time for multiple cell modifications, redosing, and reduced cost. I am working to establish a culture system to produce large numbers of allogeneic genetically modified CAR T cells at low cost, with the goal of improving safety, limiting the potential for graft-versus-host disease, and improving persistence in recipients.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events